Publikationen, an denen er mitarbeitet EMILIO BOUZA SANTIAGO (45)

2024

  1. Economic Burden of Clostridioides difficile Infection in European Countries

    Advances in experimental medicine and biology, Vol. 1435, pp. 1-12

  2. Impact of the Mediterranean Diet on the Gut Microbiome of a Well-Defined Cohort of Healthy Individuals

    Nutrients, Vol. 16, Núm. 6

2023

  1. A mutation responsible for impaired detection by the Xpert SARS-CoV-2 assay independently emerged in different lineages during the SARS-CoV-2 pandemic

    BMC Microbiology, Vol. 23, Núm. 1

  2. Characterization of the gut microbiome of patients with Clostridioides difficile infection, patients with non–C. difficile diarrhea, and C. difficile–colonized patients

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  3. Microbiome profile and calprotectin levels as markers of risk of recurrent Clostridioides difficile infection

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  4. Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection

    Open Forum Infectious Diseases, Vol. 10, Núm. 2

2022

  1. Clostridioides difficile infection epidemiology and clinical characteristics in COVID-19 pandemic

    Frontiers in Medicine, Vol. 9

  2. Nosocomial Transmission of SARS-CoV-2 Involving Vaccinated Health Care Workers

    Microbiology Spectrum, Vol. 10, Núm. 1

2021

  1. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults

    Clinical Microbiology and Infection

  2. How to: prophylactic interventions for prevention of Clostridioides difficile infection

    Clinical Microbiology and Infection, Vol. 27, Núm. 12, pp. 1777-1783

  3. Inference of active viral replication in cases with sustained positive reverse transcription-PCR results for SARS-CoV-2

    Journal of Clinical Microbiology, Vol. 59, Núm. 2

  4. Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity

    Mycoses, Vol. 64, Núm. 2, pp. 132-143

2020

  1. Clinical impact of a Clostridioides (Clostridium) difficile bedside infectious disease stewardship intervention

    JAC-Antimicrobial Resistance, Vol. 2, Núm. 3

  2. Clostridioides difficile contamination in a clinical microbiology laboratory?

    Clinical Microbiology and Infection, Vol. 26, Núm. 3, pp. 340-344

  3. Evaluation of Clostridium difficile Infection with PET/CT Imaging in a Mouse Model

    Molecular Imaging and Biology, Vol. 22, Núm. 3, pp. 587-592

  4. Factors affecting reported Clostridioides difficile infection rates; the more you look the more you find, but should you believe what you see?

    Anaerobe, Vol. 62

  5. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules

    Journal of Hospital Infection, Vol. 105, Núm. 2, pp. 319-324

  6. Prediction of poor outcome in Clostridioides difficile infection: A multicentre external validation of the toxin B amplification cycle

    Anaerobe, Vol. 61

  7. Recommendations for the diagnosis and treatment of clostridioides difficile infection: An official clinical practice guideline of the spanish society of chemotherapy (SEQ), spanish society of internal medicine (SEMI) and the working group of postoperative infection of the spanish society of anesthesia and reanimation (SEDAR)

    Revista Espanola de Quimioterapia, Vol. 33, Núm. 2, pp. 151-175

  8. Role of Clostridioides difficile in hospital environment and healthcare workers

    Anaerobe, Vol. 63